» Articles » PMID: 38720269

Molecular Markers of Artemisinin Resistance During Falciparum Malaria Elimination in Eastern Myanmar

Abstract

Background: Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaquine (three rounds at monthly intervals) was conducted. The prevalence of artemisinin resistance during the elimination campaign (2013-2019) was characterized.

Methods: Throughout the six-year campaign Plasmodium falciparum positive blood samples from symptomatic patients and from cross-sectional surveys were genotyped for mutations in kelch-13-a molecular marker of artemisinin resistance.

Result: The program resulted in near elimination of falciparum malaria. Of 5162 P. falciparum positive blood samples genotyped, 3281 (63.6%) had K13 mutations. The prevalence of K13 mutations was 73.9% in 2013 and 64.4% in 2019. Overall, there was a small but significant decline in the proportion of K13 mutants (p < 0.001). In the MDA villages there was no significant change in the K13 proportions before and after MDA. The distribution of different K13 mutations changed substantially; F446I and P441L mutations increased in both MDA and non-MDA villages, while most other K13 mutations decreased. The proportion of C580Y mutations fell from 9.2% (43/467) before MDA to 2.3% (19/813) after MDA (p < 0.001). Similar changes occurred in the 487 villages where MDA was not conducted.

Conclusion: The malaria elimination program in Kayin state, eastern Myanmar, led to a substantial reduction in falciparum malaria. Despite the intense use of artemisinin-based combination therapies, both in treatment and MDA, this did not select for artemisinin resistance.

Citing Articles

Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low Malaria Transmission Setting in Southern Zambia.

Martin A, Sadler J, Simkin A, Musonda M, Katowa B, Matoba J medRxiv. 2025; .

PMID: 39802768 PMC: 11722444. DOI: 10.1101/2025.01.02.24319706.


Artemisinin-resistant malaria.

White N, Chotivanich K Clin Microbiol Rev. 2024; 37(4):e0010924.

PMID: 39404268 PMC: 11629630. DOI: 10.1128/cmr.00109-24.


Molecular survey of pfmdr-1, pfcrt, and pfk13 gene mutations among patients returning from Plasmodium falciparum endemic areas to Turkey.

Avci K, Karakus M, Yasar K Malar J. 2024; 23(1):286.

PMID: 39334180 PMC: 11437951. DOI: 10.1186/s12936-024-05107-6.

References
1.
White N . Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malar J. 2019; 18(1):338. PMC: 6777025. DOI: 10.1186/s12936-019-2955-z. View

2.
Witkowski B, Duru V, Khim N, Ross L, Saintpierre B, Beghain J . A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2016; 17(2):174-183. PMC: 5266792. DOI: 10.1016/S1473-3099(16)30415-7. View

3.
Imwong M, Nguyen T, Tripura R, Peto T, Lee S, Maung Lwin K . The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J. 2015; 14:381. PMC: 4590703. DOI: 10.1186/s12936-015-0906-x. View

4.
Price R, Uhlemann A, van Vugt M, Brockman A, Hutagalung R, Nair S . Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006; 42(11):1570-7. PMC: 4337983. DOI: 10.1086/503423. View

5.
McLean A, Indrasuta C, Khant Z, Phyo A, Maung S, Heaton J . Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infect Dis. 2021; 21(11):1579-1589. PMC: 7614510. DOI: 10.1016/S1473-3099(20)30997-X. View